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Abstract
Neurons that produce gonadotropin-releasing hormone (GnRH) are the final common pathway by
which the brain regulates reproduction. GnRH neurons are regulated by an afferent network of
kisspeptin-producing neurons. Kisspeptin binds to its cognate receptor on GnRH neurons and
stimulates their activity, which in turn provides an obligatory signal for GnRH secretion—thus
gating down-stream events supporting reproduction. We have developed kisspeptin antagonists to
facilitate the direct determination of the role of kisspeptin neurons in the neuroendocrine
regulation of reproduction. In vitro and in vivo studies of analogues of kisspeptin-10 with amino
substitutions have identified several potent and specific antagonists. A selected antagonist was
shown to inhibit the firing of GnRH neurons in the brain of the mouse and to reduce pulsatile
GnRH secretion in female pubertal monkeys; the later supporting a key role of kisspeptin in
puberty onset. This analogue also inhibited the kisspeptin-induced release of luteinizing hormone
(LH) in rats and mice and blocked the post-castration rise in LH in sheep, rats and mice,
suggesting that kisspeptin neurons mediate the negative feedback effect of sex steroids on
gonadotropin secretion in mammals. The development of kisspeptin antagonists provides a
valuable tool for investigating the physiological and pathophysiological roles of kisspeptin in the
regulation of reproduction and could offer a unique therapeutic agent for treating hormone-
dependent disorders of reproduction, including precocious puberty, endometriosis, and metastatic
prostate cancer.
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INTRODUCTION
The production of gonadotropin-releasing hormone (GnRH) by neurons that reside in the
forebrain is the primary effector of gonadotropin secretion, which is critical for downstream
regulation of gamete and sex steroid hormone production by the testes and ovaries. Neurons
that produce GnRH are modulated by feedback actions of sex steroids and a host of other
factors, including photoperiod, metabolic signals and stress (Porkka-Heiskanen et al., 1997;
Richardson et al., 2004; Centeno et al., 2007). However, the afferent inputs transducing
these effects into changes in GnRH secretion have remained elusive. A key candidate
transducer emerged in 2003 through genetically-linked mutations in a G protein-coupled
receptor (gpr-54) (de Roux et al., 2003; Seminara et al., 2003). Gpr-54 was known to be the
cognate receptor for neuropeptides, called kisspeptins, which are differentially processed
from a precursor protein encoded by the KiSS-1 gene (Kotani et al., 2001), originally
identified as a metastasis inhibitor (Lee et al., 1996). Kisspeptin/gpr-54 signaling has since
emerged as a linchpin in the neuroendocrine regulation of reproduction (Popa et al., 2008).
Subsequently it was learned that kisspeptin-producing neurons directly innervate GnRH
neurons and that kisspeptins are potent secretagogues for GnRH and LH (Gottsch et al.,
2004; Irwig et al., 2004; Popa et al., 2008). Moreover, kisspeptin neurons have been
implicated as conduits that relay humoral and environmental signals to GnRH neurons
(Castellano et al., 2005; Smith et al., 2005; Estrada et al., 2006; Greives et al., 2006; Revel
et al., 2006). Thus, kisspeptin/gpr-54 signaling represents a nodal point in the
neuroendocrine regulation of reproduction and a potential therapeutic target.
Kisspeptin and gpr-54 are expressed in a number of other tissues but clear functions have
not been established. Kisspeptin immunoreactivity is markedly elevated in pregnancy
(Horikoshi et al., 2003), produced by trophoblast cells (Janneau et al., 2002) and inhibits
trophoblast invasion (Bilban et al., 2004). Kisspeptins have also been reported to stimulate
vasoconstriction (Mead et al., 2006), effect synaptic transmission (Arai et al., 2005) and
insulin secretion (Hauge-Evans et al., 2006).
Through their modulation of the hypothalamic-pituitary-gonadal (HPG) axis, GnRH
analogues are extensively employed to treat hormone-dependent diseases including
prostatic, breast and ovarian cancers, endometriosis, uterine fibroids and precocious puberty,
as well as to induce ovulation for infertility and IVF (Conn and Crowley, 1994; Millar et al.,
2004). Since kisspeptin exerts such a powerful stimulatory effect on GnRH and
gonadotropin secretion, it is plausible that intervention at the level of the kisspeptin/gpr-54
signaling may have potential for treatment of these conditions, possibly with more subtly
regulated control than achieved with GnRH analogues.
The development of kisspeptin antagonists would therefore provide the wherewithal to
elucidate the role of kisspeptin in reproductive development and puberty, in positive and
negative gonadal feedback as well as in metabolic and stress effects on the reproductive
system.
We report on a systematic structure-activity study of kisspeptin analogs and the
development of potent and specific antagonists, and present a detailed in vivo analysis of the
effects in rodents, sheep and monkeys. The studies reveal a pivotal role for kisspeptin in
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controlling puberty and in steroid hormone feedback on gonadotropin secretion underlining
the potential wide utility of these antagonists for research and clinical applications.
MATERIAL AND METHODS
Peptides
Materials—Human kisspeptin-10 and peptide analogues 186-191, 200-203, 206-213 and
228-248 were custom synthesized by EZBiolabs. Peptide analogues for preliminary studies
were synthesized to a purity of >80% (range 83-99% measured by HPLC) and peptide 234,
which was selected for detailed studies was synthesized at a purity of >95%. The
authenticity of peptides was confirmed by mass spectrometry. The source of all other
reagents is indicated in the text.
In vitro assays for antagonist activity
Cell Culture—Chinese hamster ovary (CHO) cells stably-expressing the human gpr-54
receptor (CHO/gpr-54) were obtained from Prof. G. Vassart, Univ. Brussels. The cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM; Sigma) supplemented with
10% fetal calf serum, 2% glutamine and 1% penicillin (10,000units/ml)/streptomycin
(10,000 mg/ml) at 37°C in a humidified 5% CO2 atmosphere.
Whole Cell Receptor Binding Assay—Assays were preformed as previously described
(Lu et al., 2007; Coetsee et al., 2008). Briefly, kisspeptin-10 was prepared at 1:100 dilution
in HEPES modified DMEM supplemented with 0.1% Bovine Serum albumin and 125I-
labelled Kisspeptin-10 (100,000 cpm/0.5mls). Cell monolayers were placed on ice and
exposed to 0.5mls peptide (10pM-10uM); the cells were then incubated at 4°C for 3hr. After
3hrs, cells were washed twice with ice cold DPBS (with Calcium and Magnesium) and then
0.5mls 0.1M Sodium Hydroxide (NaOH) were added to cells for 20 minutes, while shaking.
Lysates were transferred to plastic tubes and bound radioactivity counted on the Wallac
1470 Wizard gamma counter (PerkinElmer and Analytical Sciences (UK) Ltd,
Buckinghamshire, UK).
Inositol Phosphate (IP) Stimulation Assay—Prior to stimulation CHO/gpr-54 cells
were washed twice with Dulbecco’s phosphate-buffered saline (DPBS; without calcium or
magnesium) then incubated overnight with 3H-myoinositol, labeled HEPES-modified
DMEM with 1% penicillin/streptomycin at 37°C. HEPES-modified DMEM supplemented
with 1% penicillin/streptomycin and 1% lithium chloride (0.5 ml) was added to cells for 30
min at 37° C to block IP hydrolysis. Cells were then stimulated with 0.5 ml kisspeptin-10
and analogues (10 pM-1 μM) diluted at 1:100 in the above media for 1 h at 37° C, then with
10 mM formic acid at 4° C for 1 h to lyse cells. Lysates were transferred to plastic tubes
containing 0.5 ml Dowex resin to bind the radioactive IP and the resin was then washed with
1ml water. The resin was next washed with 60 mM ammonium formate/5mM sodium
tetraborate followed by 1M ammonium formate/0.1M formic acid to release the bound
radiation. Then 800 μl of the radioactive solution were transferred to scintillation vials
containing 2.5 ml scintillation fluid and radioactivity counted on a Beta counter for 60 sec.
Experiments were repeated 3-5 times. IP production was plotted as mean values ± SEM and
analyzed by using a two-way ANOVA followed by Bonferroni post hoc test (p≥0.05).
Inositol Phosphate (IP) Antagonism Assay—CHO/gpr-54 cell monolayers were
stimulated with 0.25ml kisspeptin (10nM) alone or in combination with 0.25ml peptide
analogues (100pM—1μM), to investigate the inhibition of kisspeptin stimulation of IP
production. Experiments were repeated 3-5 times. IP production was plotted as mean values
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± SEM and analyzed using a two-way ANOVA followed by Bonferroni post hoc test
(p≥0.05).
GnRH neuron firing
Animals—Firing of GnRH neurons were recorded in brain slices from transgenic female
mice in which GFP is genetically targeted to GnRH neurons (Suter et al., 2000). Mice were
housed on a 14 h light, 10 h dark cycle, with lights off at 1630 h, and were maintained on
Harlan 2916 rodent chow (Harlan) and water ad libitum. All procedures were approved by
the Animal Care and Use Committee of University of Virginia and were conducted within
the guidelines of the National Research Council’s Guide for the Care and Use of Laboratory
Animals. Adult female GnRH-GFP mice were ovariectomized under isoflurane (Abbott
Laboratories) anesthesia. Postoperative analgesia was provided by a long-acting local
anesthetic (0.25% bupivicaine; 7.5 μl/site; Abbott Laboratories). At the time of surgery,
mice received Silastic (Dow Corning) capsules containing 0.625 μg estradiol in sesame oil.
Recordings were done 2-4 days after surgery in the AM, when estradiol has been
demonstrated to have a negative feedback effect (Christian et al., 2005). No more than four
cells from a single animal were recorded, all in different slices.
Brain slice preparation—Brain slices were prepared using previously described method
(Nunemaker et al., 2002). Briefly, all solutions were bubbled with a 95% O2/5% CO2
mixture throughout the experiments and for at least 15 min before exposure to the tissue.
The brain was rapidly removed and placed in ice-cold, high-sucrose saline solution
containing 250 mM sucrose, 3.5 mM KCl, 26 mM NaHCO3, 10 mM glucose, 1.25 mM
Na2HPO4, 1.2 mM MgSO4, and 2.5 mM MgCl2. Coronal 300-μm brain slices were cut with
a Vibratome 3000 (Technical Products, International, Inc., St. Louis, MO). Slices were
incubated for 30 min at 30–32C in a solution of 50% high-sucrose saline and 50% normal
saline (NS) containing 135 mM NaCl, 3.5 mM KCl, 10 mM glucose, 1.3 mM Na2HPO4, 1.2
mM MgSO4, and 2.5 mM CaCl2 and then were transferred to a solution of 100% NS at
room temperature and kept at least 30 min and no more than 6 h before recording.
Electrophysiological recordings—Targeted extracellular recordings (also known as
loose-patch) were used to study effects of kisspeptin-10 and peptide 234 on GnRH neuron
firing activity (Pielecka and Moenter, 2006). Because low resistance seals (<50 MΩ) do not
influence the cell membrane this approach is a minimally invasive method for monitoring
the endogenous electrical activity of a single cell. Although these events are not action
potentials per se, they accurately reflect changes in the action potential firing rate. For
simplicity, we have used the phrases firing rate, firing pattern, and/or firing activity to refer
to these events.
Individual brain slices were placed in a recording chamber continuously superfused with
oxygenated NS solution and kept at 29–31 C. Cells were visualized with an Olympus
BX50WI upright fluorescent microscope with infrared differential interference contrast
(Opelco). GnRH neurons were identified by brief illumination at 470 nm to visualize the
GFP signal. Patch borosilicate pipettes (World Precision Instruments), which ranged from
1.5–3Ω M were filled with normal HEPES-buffered solution containing 150 mM NaCl, 10
mM HEPES, 10 mM glucose, 2.5 mM CaCl2, 1.3 mM MgCl2, and 3.5 mM KCl. Pipettes
were placed in contact with the GnRH neurons using an MP-285 micromanipulator (Sutter
Instruments). Seal resistances ranged from 8 MΩ and either remained stable or increased
during recording up to as high as 50 MΩ. Current traces were obtained using an EPC-8
amplifier (HEKA) with the PulseControl XOP (Instrutech) running in Igor Pro
(Wavemetrics) on the G4 Macintosh computer (Apple Computer) to acquire data. A voltage-
Roseweir et al. Page 4













clamp mode with a pipette holding potential of 0 mV, filtering at 10 kHz, digitized with an
ITC-18 acquisition interface (Instrutech) was used for the recordings.
Experimental design—Human kisspeptin-10, 1nM, (Phoenix Pharmaceuticals) was
applied via the incubation bath. Different doses (1nM, 10nM, 100nM) of peptide 234 were
used to examine its antagonistic action on kisspeptin-10 activation of gpr-54. Positive
control cells were recorded for a 10-min stable baseline, and then treated with kisspeptin-10
for 5 min, followed by a 15-min washout. Experimental cells were recorded for a 5-min
stable baseline in NS, followed by 10 min in peptide 234 (1, 10 or 100 nM), then 5 min in
kisspeptin-10 plus the same dose of antagonist, followed by a wash in NS. Washing with a
solution containing antagonist yielded similar results (1 nM peptide 234, n=5 cells, not
shown). One cell in the 10 nM peptide 234 group showed no activity; addition 15 mM KCl
confirmed cell viability and recording integrity.
Data analysis—Using programs written for Igor Pro, extracellularly-recorded events were
counted and binned at 1-min intervals to identify changes in firing rate of GnRH neurons.
Binned event data were analyzed using Microsoft Excel (Microsoft Corp) for the mean
firing rate before kisspeptin-10 treatment (baseline, note this is during peptide 234 treatment
in cells in the antagonist treatment groups) during kisspeptin-10 application (treatment), and
during washout. For cells in the antagonist treatment group firing rates in NS vs. antagonist
before kisspeptin-10 application were also compared. Mean firing rate was determined by
dividing the total number of events detected by the duration of recording in each condition;
two minutes were skipped after drug changes to eliminate transition periods. Since GnRH
neuron firing activity changes with time (Nunemaker et al., 2002; Pielecka and Moenter,
2006) the fold change for each treatment group was calculated. Groups were compared
using ANOVA followed by Bonferroni post hoc test.
Effects of peptide 234 on GnRH release in female rhesus monkeys
Animals—Four female rhesus monkeys, born and raised in the Wisconsin National Primate
Research Center, were used in this study. They were housed in pairs (cages 172 × 86 × 86
cm) in rooms with 12 h of light 12 h of darkness and controlled temperature (22 °C). The
animals were fed a standard diet of Harlan 20% Protein Primate Diet twice each day,
supplemented with fresh fruit several times per week. Water was available ad libitum. The
protocol for this study was reviewed and approved by the Animal Care and Use Committee,
University of Wisconsin, and all experiments were conducted under the guidelines
established by the NIH and USDA.
Experimental design—The effects of peptide 234 on GnRH release were examined using
the microdialysis method. This method allows collection of dialysate samples for GnRH
measurement while peptide 234 was infused through the semi-permeable membrane, as
described previously (23,24). Peptide 234 dissolved in CNS perfusion fluid was infused in
the stalk median eminence region through the microdialysis probe for 30 min while
dialysates were continuously collected. For a control, vehicle was similarly infused. Each
animal was examined with peptide 234 (10 nM concentration) or vehicle at a random order
in the same experiment a 2 hour-minimum interval between two challenges. Two of the 4
animals were examined twice in separate experiments totaling 6 experiments. During the
entire experiment monkeys were placed in proximity to a companion monkey, given
constant access to food and water, and were provided frequently with fruit, cereal, raisins
and other snacks. The mean age of sampling was 33.1±0.4 months.
Cranial pedestal implantation—For collection of perfusates in the stalk-median
eminence region, we used the microdialysis method, as previously described (Keen et al.,
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2008). Prior to experiments, monkeys at 29.1±1.2 months of age (body weight: 3.6±0.1 kg)
were well-adapted to the primate chair, experimental environment, and investigator. They
were implanted with a cranial pedestal under isoflurane anesthesia, similar to those
described previously for push-pull perfusion method (Gearing and Terasawa, 1988).
Animals were allowed to recover for at least 1 month prior to experimentation.
Microdialysis methods—On the day of experiment the monkey was placed in the
stereotaxic apparatus under ketamine (15 mg/kg b.w.) and medetomidine (0.03-0.05 mg/kg
b.w.) anesthesia. The custom-made guide cannula (CMA 12) consisted of a stainless steel
shaft (76.0 mm in length, 0.91 mm o.d.) and a removable stainless steel stylet (96.0 mm in
length, 0.6 mm o.d.), which extruded 20 mm from the guide cannula tip. It was inserted into
the skull 5 mm above the S-ME with a hydraulic microdrive unit (MO95-B). The microdrive
unit allowed for accurate three-dimensional adjustment of the tip location. The x, y, and z
coordinates for the S-ME were calculated using ventriculographs and the final radiographs
taken during cranial pedestal implantation surgery. Cannula placement was confirmed with
radiographic visualization. Following placement of the guide cannula, the monkey was
removed from the stereotaxic apparatus and placed into a primate chair. Upon proper
placement in the chair, the inner stylet was removed from the guide cannula and a custom-
made microdialysis probe (a stainless steel shaft 96.0 mm in length, 0.6 mm o.d.), fitted with
a membrane (5 mm in length, 0.5 mm o.d.), was inserted into the S-ME through the guide
cannula as described previously (Frost et al., 2008)’(Keen et al., 2008). To reverse the
effects of medetomidine, atipamazole (0.15-0.25mg/kg) was injected (i.v.) into the animal.
The animal was fully awake within 1 h after probe insertion.
A CNS perfusion fluid consisting of NaCl 147mM, KCl 2.7mM, CaCl2 1.2mM, MgCl2
0.85mM, purchased from CMA/Microdialysis with bacitracin (4 U/ml) added, was infused
through the inflow tubing at 2 μl/min with the CMA/102 microdialysis pump outfitted with a
1 or 2.5 ml Hamilton gas tight syringe (Reno). Perfusates were continuously collected at 10
min intervals for up to 12 h through the outflow tubing into 12 × 75 mm borosilicate tube,
on ice with a fraction collector (Model FC203B). The perfusate samples were immediately
frozen on dry ice and stored at -80 °C.
GnRH RIA—RIA was conducted with the antiserum R42 kindly provided by Dr. Terry Nett
(Colorado State University), as described previously (Gearing and Terasawa, 1988). Assay
sensitivity was 0.02 pg/tube and intra and interassay coefficients of variation were 8.1% and
11.3%, respectively.
Data analysis—Peaks of GnRH release were identified using the PULSAR algorithm as
described previously (Merriam and Wachter, 1982). The mean value of a 30 min period of
GnRH collection before and after peptide 234 (or vehicle) challenge was calculated in each
experiment. Subsequently, the means (± sem) of all experiments during each time period
were calculated for statistical comparison. The difference between before, during and after
the treatment (within treatment) as well as between treatments (peptide 234 vs. vehicle) was
examined using 2-way analysis of variance followed by Tukey’s multiple comparison test.
Differences were considered significant at P < 0.05.
Dynamic studies on peptide 234 inhibition of LH in male rats
Experimental Design—Adult male rats (BW: 280-310 g) bred in the vivarium of the
University of Córdoba were used. The animals were maintained under constant conditions of
light (14 h of light, from 0700 h) and temperature (22 C), and, before cannula implantation,
were kept in groups of four rats per cage with free access to pelleted food and tap water.
Experimental procedures were approved by the Córdoba University Ethical Committee for
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animal experimentation and were conducted in accordance with the European Union
normative for care and use of experimental animals.
The animals were implanted with icv cannulae under light ether anaesthesia and caged
individually thereafter. To allow delivery of compounds into the lateral cerebral ventricle,
the cannulae were lowered to a depth of 4 mm beneath the surface of the skull; the insert
point was 1 mm posterior and 1.2 mm lateral to bregma. Functional tests were conducted at
least 24-48 h after cannula implantation.
Pharmacological tests in intact males involved 5 μl injections at 60 min intervals (icv) of
1nmol doses of the peptide 234. The last injection was accompanied by the injection of an
effective (but sub-maximal) dose of 100 pmol kisspeptin-10 (Phoenix Pharmaceuticals Ltd).
Animals injected with vehicle (physiological saline) served as controls. Blood samples (250
μL) were taken by jugular venipuncture at 15- and 60-min following each icv injection. In
addition, blood samples were taken immediately before initiation of the experiment (time: 0-
min) and at 120-min after last injection (time: 240-min). Experimental procedures and
kisspeptin doses were selected on the basis of previous studies (Castellano et al., 2005;
Navarro et al., 2005; Adachi et al., 2007). For each time-point, 10-12 samples were taken
per group.
In addition, repeated icv injection of the peptide 234 was also conducted in orchidectomized
(ORX) rats. The animals were subjected to bilateral ORX via the scrotal route, and after 1-
wk after surgery were subjected to cannula implantation as described above. The test
involved three intracerebral injections of the antagonist (1 nmol; at 0-, 60- and 120-min of
the procedure) and blood sampling by jugular venipuncture in basal conditions (0-min) and
15-min after each icv injection. Additional blood samples were obtained at 180- and 240-
min after central administration of peptide 234. For each time-point, 10-12 samples were
taken per group.
Hormone Measurements—Serum LH levels were measured in a volume of 50 μl using a
double-antibody method and radioimmunoassay kits supplied by the NIH (Dr. AF Parlow,
NIDDK). Rat LH-I-10 was labeled with 125I using Iodo-Gen precoated tubes, following the
instructions of the manufacturer (Pierce), and hormone concentrations were expressed using
reference preparation LH-RP-3 as standard. Intra- and inter-assay coefficients of variation
were below 8 and 10%, respectively. The sensitivity of the assay was 5 pg/tube. In addition,
serum testosterone (T) measurements were selectively conducted in blood samples taken 60-
min after co-administration of kp-10 and peptide 234 (Time: 180-min). To this end, a
commercial kit from MP Biomedicals was used, following the instructions of the
manufacturer. The sensitivity of the assay was 0.1 ng/tube and the intra-assay coefficient of
variation was 4.5 %. For each hormone, all samples were measured in the same assay.
Accuracy of hormone determinations was confirmed by assessment of rat serum samples of
known hormone concentrations used as external controls.
Data analysis—Hormonal determinations were conducted in duplicate, with a minimal
total number of 10 samples per group. When appropriate, in addition to individual time-
point measurements, integrated LH secretory responses were calculated as the area under the
curve (AUC), following the trapezoidal rule. Hormonal data are presented as mean ± SEM.
Results were analyzed for statistically significant differences using Student t-test or
ANOVA followed by Student-Newman-Keuls multiple range test (SigmaStat 2.0). P≤0.05
was considered significant.
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Effects of peptide 234 on LH levels in male mice
Animals—Adult male mice (7-8 weeks old) were purchased from Jackson Laboratories and
housed on a 14h light, 10h dark cycle (lights off at 1800h) in groups of 3-5 mice/cage.
Rodent chow (Harlan Teklad 7912) and water were available ad libitum. All procedures
were approved by the Animal Care and Use Committee of the University of Washington.
Experimental Design—The effects of peptide 234 on the elevated LH secretion of
castrated animals were determined. Adult male mice were either castrated under isoflurane
anesthesia or left intact. One week later, mice were given two icv freehand infusions (3 μl
each) of either vehicle (20% propylene glycol, 13% DMSO) or peptide 234 (15 nmol or
1nmol) into the lateral ventricle, as previously described (Laursen and Belknap, 1986;
Hohmann et al., 2000; Krasnow et al., 2003). The two infusions were identical for each
animal and were administered 60 min apart, each under light isoflurane anesthesia. Blood
was collected retro-orbitally 30 min after the second infusion and centrifuged for 6 min.
Plasma was collected and stored at -20C until assay for LH. All infusions were performed
between 0800h and 1200h. Groups contained n=6-8 animals.
Having found a strong antagonistic effect of the higher dose (15 nmol) of peptide 234, an
additional dose response study was then performed to better specify effective doses of the
analogue. Following the same procedure as before, a new cohort of castrated male mice was
given two icv infusions of either vehicle or one of three doses of peptide 234 (1 nmol, 5
nmol, 15 nmol), and blood collected 30 min after the second infusion. Groups contained
n=6-8 animals.
In the next set of experiments, we determined whether a single infusion of peptide 234
would have inhibitory effects on LH secretion, and whether the antagonistic effects of
peptide 234 were specific to kisspeptin signaling. First, castrated male mice (and a control
group of intact males) were given a single icv infusion (3 μl) of either vehicle or peptide 234
(5 nmol, 15 nmol), and blood was collected retro-orbitally 30 min later. Next, a separate
cohort of intact males were treated first with a 3 μl icv infusion of vehicle or peptide 234 and
then, 5 min later, administered a second 3 μl icv infusion of either kisspeptin (Phoenix
Pharmaceuticals) or aCSF. Blood was collected 30 min after the second infusion and
assayed for LH. The dose of kisspeptin was 100 fmol (previously shown to be effective in
eliciting an LH response in mice) and the dose of peptide 234 was 100 pmol. Groups
contained n=6-8 animals
Hormone Measurements and Statistical Analyses—For all experiments, serum LH
levels were measured via radioimmunoassay by the University of Virginia Ligand Assay
Core Lab. Samples were assayed in duplicate, and the intra- and inter-assay coefficients of
variation were below 6.1% and 6.7%, respectively. The sensitivity of the assay was 0.04 ng/
ml. For each experiment, all samples were measured in the same assay. Values are presented
as group means ± S.E., and differences between groups were determined using one-way
ANOVA, with post-hoc analysis determined by Fisher’s PLSD (Statview 5.0.1). In all cases,
statistical significance level set at p<0.05.
Effect of peptide 234 on LH in ovariectomised ewes
Experimental procedure—All experimental procedures were conducted under a protocol
approved by the Monash School of Biomedical Sciences Animal Ethics Committee. Adult
Corriedale ewes were housed under natural lighting and were bilaterally ovariectomized
(OVX) at least 1 month before any experimental manipulations. Permanent indwelling third
cerebral ventricular (3V) cannulae were implanted in a subsequent surgical procedure as
previously described (Barker-Gibb et al., 1995). Approximately 2 weeks after 3V surgery,
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one external jugular vein was cannulated for blood sampling and animals housed in single
pens; cannulae were kept patent with heparinized saline. Ewes were assigned to two
treatment groups (4/group); peptide 234 (diluted in artificial cerebrospinal fluid, aCSF; 150
mM NaCl, 1.2 mM CaCl2, 1 mM MgCl2, 2.8 mM KCl) or control (aCSF only). The
following day, infusion lines were connected to 3V cannulae and blood sampling
commenced at 07.00 h. Samples were collected every 10 min. After 3 h of sampling, peptide
234 (or control) was infused into the 3V at a dose of 40 μg/h for 1 h, with an initial loading
dose of 10 μg. Both peptide 234 and vehicle were infused at 200 μl/h using Graseby®
MS16A infusion pumps (Smith Medical Australasia Pty. Ltd.). After infusion, 3V lines
remained in place and blood sampling continued for a further 2 h (total of 6 h). Plasma was
harvested immediately from samples, and frozen at -20 C until assayed.
Plasma LH concentrations were measured in duplicate, with NIH-oLH-S18 as standard
(Barker-Gibb et al., 1995). Assay sensitivity was 0.1 ng/ml and the intra-assay coefficient of
variation was less than 10% over the range of 0.3 - 12.8 ng/ml. Pulse analysis of the plasma
LH data was as previously described (Clarke, 1993).
Plasma prolactin concentrations were measured in duplicate using Sigma, Lot 114F-0558,
NOL-7135 as standard (Thomas et al., 1990). The sensitivity of the assay was 1 ng/ml. Intra-
assay CV was less than 10% between 1 and 22 ng/ml.
Plasma cortisol concentrations were assayed in duplicate using antiserum no. 3368
(Bioquest Ltd) and 125I-labeled cortisol (Amersham Pharmacia Biotech Ltd). The sensitivity
of the assay was 3 ng/ml. Intra-assay CV was less than 10% between 3 and 18 ng/ml, and
the inter-assay CV was 15%.
Data Analysis—For data analysis of LH, prolactin and cortisol, the mean plasma value in
each ewe was calculated for the period before (0-180 min), during (180-240 min), and after
(240-360 min) the infusion. In addition, the mean LH pulse amplitude for each ewe was also
calculated before, during, and after the infusion. Repeated Measures ANOVAs were used to
determine the effect of peptide 234 treatment on hormone levels over each period, and
where appropriate one-way ANOVAs were employed to assess specific difference within
each period.
RESULTS
Effects of substitutions of amino acids within kisspeptin-10 on stimulation of inositol
phosphate (IP) release in CHO cells stably-expressing human gpr-54
As kisspeptin-10 is the minimal sequence required for full receptor binding and activation,
we explored the effect of systematic substitution of amino acids in this region monitoring
the inhibition of 10nM kisspeptin-10 stimulation of IP production in cells stably-expressing
the human gpr-54. Because the C-terminal sequence RF.NH2 is conserved in this large and
ancient peptide family, we reasoned that this is essential for receptor binding and focused
our attention on the preceding eight amino acids. We truncated the N-terminal five amino
acids and introduced various substitutions with D-amino acids. This resulted in a loss of
efficacy in IP production and a weak and incomplete ability to inhibit IP stimulation by
10nM kisspeptin-10 (See supporting information (SI) Table S1). This indicated the first five
amino acids are important for receptor activation. We then substituted residues alone or in
combination in the full ten amino acid peptide, and monitored the effect this had on intrinsic
IP stimulation and any inhibitory effects these substitutions had on IP stimulation by 10nM
kisspeptin-10. This systematic substitution of amino acids allowed us to develop a range of
analogues with partial agonistic and antagonistic properties at gpr-54 (see Table S1). Many
of these analogues incorporated a glycine substitution for Ser5 in combination with a D-
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amino acid (tryptophan or leucine) at Leu8. Although these substitutions alone did
significantly (P<0.01) inhibit 10nM kisspeptin-10 stimulation of IP, they generally did not
reduce this stimulation to basal levels (see Table S1).
To develop full antagonists, further D-amino acid substitutions were made at Tyr1, Asn2 and
Trp3. The most effective antagonists with substitutions in these positions were peptides 230,
232, 233, 234, 235 and 236 which alone had little or no stimulation of IP, but had IC50s of
<10-8M and a maximal inhibition of 66-93% of kisspeptin stimulation of IP (see table S1).
The most complete inhibition was achieved with D-Ala1 substitution (see table S1 (234) and
Fig. 1). This combination of substitutions inhibited 10nM kisspeptin-10 stimulation of IP by
93%, with an IC50 of 7nM and had no intrinsic IP stimulation, signifying high antagonist
activity. The studies have also highlighted the significance of the glycine substitution at Ser5
and D-tryptophan at Leu8 combined with appropriate substitutions in the N-terminus. The
active analogs displayed high binding affinities in competition with 125I-kisspeptin-10. Most
decamer analogues tested bound with an EC50 similar to kisspeptin, for example peptide
234 had a binding affinity of 2.7nM (see Fig. S1). However, the 5aa analogues had lower
binding affinities than the full decamer analogues with some unable to bind the receptor
(data not shown).
Peptide 234 inhibits kisspeptin-10 stimulation of GnRH neuron firing
As has been demonstrated previously (Han et al., 2005; Pielecka-Fortuna et al., 2008), 1nM
kisspeptin-10 markedly increased GnRH neuron firing activity (see Fig. 2A and C). Under
these experimental conditions, there was no effect on GnRH neuron firing activity of peptide
234 alone (1nM pre 0.2 ± 0.1 Hz, post 0.3 ± 0.1Hz, n=5, P>0.05; 10nM pre 0.3 ± 0.2 Hz,
post 0.3 ± 0.2Hz, n=6, P>0.05; 100nM pre 0.5 ± 0.1Hz, 0.6 ± 0.1 Hz, n=7, P>0.05, paired t
test). In contrast to the lack of effect of peptide 234 on basal firing, pretreatment with this
peptide blocked the response to 1nM kisspeptin-10 (P<0.001 for all doses) compared to cells
treated with kisspeptin-10 alone (see Fig. 2B and C).
Peptide 234 inhibits pulsatile GnRH release in pubertal female rhesus monkeys
Since peptide 234 inhibited GnRH neuronal firing we examined whether it also inhibited
GnRH release in pubertal female rhesus monkeys using methods previously described (Frost
et al., 2008; Keen et al., 2008). Infusion of 10 nM peptide 234 over 30 min through a
microdialysis probe located in the stalk-median eminence region promptly and consistently
suppressed GnRH pulses as well as mean GnRH levels but did not affect basal levels (see
Fig. 3A and C). In contrast, vehicle infusion through the probe did not cause any significant
changes in GnRH release (see Fig. 3B and D). The peptide 234-induced GnRH suppression
was significantly different from values prior to peptide 234 infusion as well as those from
the vehicle control (for both p<0.05). Based on our previous assessment that the dialysis
membrane passes ∼10% of peptides with a similar size to 234 (Frost et al., 2008), it is
estimated that the concentration of peptide 234 in the stalk-median eminence region was 1
nM.
Peptide 234 inhibits kisspeptin-10 stimulated LH in intact male rats and the increase in LH
after castration
The effects of peptide 234 were tested in vivo using adult male rats. Pharmacological tests
involved repeated (x3) intracerebral ventricular (icv) injections of 1nmol peptide 234 and
serial blood sampling, in order to assess potential effects of antagonists on basal LH levels.
The third injection was accompanied by co-administration of a submaximal dose (100 pmol)
of kisspeptin-10 and a 1nmol dose of peptide 234, to monitor the ability to inhibit
kisspeptin-10 stimulation of LH and testosterone via activation of GnRH neurons.
Administration of 1 nmol peptide 234 icv did not significantly modify basal LH levels at
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anytime tested after injection. Central injection of 100 pmol kisspeptin-10 to vehicle-treated
animals (at 120-min) evoked the expected rise in serum LH levels with a net LH secretory
mass (AUC) of 527 ± 43. In spite of its lack of effect on basal LH levels, co-administration
of peptide 234 blunted the LH secretory responses induced by kisspeptin-10, with a
significant (P<0.01) reduction in the net LH secretory mass (AUC) to 328 ± 56 during the
120-min period following co-injection of peptide 234 and kisspeptin-10. In good agreement,
testosterone levels at 60-min after combined injection of peptide 234 and kisspeptin-10 (1.58
± 0.1) were significantly (P<0.01) lower than in animals injected with kisspeptin-10 alone
(2.17 ± 0.2). LH levels were elevated in castrated rats over the 240 min monitoring period.
Administration of 1nmol peptide 234 at 0-, 60 and 120 min tended to reduce serum LH
levels in castrated males; a reduction that reached statistical significance at 240 min (see Fig.
4B).
Peptide 234 inhibits LH in castrated male mice and kisspeptin-10 stimulated LH in intact
male mice
Peptide 234 showed strong antagonistic actions on LH levels in mice. As with the studies in
male rats, peptide 234 did not significantly alter plasma LH levels in intact male mice
(p>0.30 versus vehicle controls; data not shown). However, two infusions of peptide 234 at
15 nmol inhibited LH levels in castrated males compared with the elevated LH levels of
vehicle-treated castrated males (p<0.05; see Fig. 5A). The low dose (15 pmol) was
ineffective. The subsequent dose-response study confirmed this finding, with all three doses
of peptide 234 (1 nmol, 5 nmol, 15 nmol) reducing LH levels of castrated males to levels
observed in intact males (p<0.01) for all 3 doses relative to vehicle-treated castrates (see Fig.
5B). Similar to two infusions of peptide 234, a single infusion of peptide 234 (5 nmol or 15
nmol) eliminated the post-castration rise in LH (p<0.05) relative to vehicle-treated castrates
(see Fig. 5C). The inhibition of LH levels in castrated mice after treatment with peptide 234
appears to be due to specific inhibition of kisspeptin signaling (rather than nonspecific
effects or effects on other neuroendocrine systems) because pre-treatment of intact mice
with peptide 234 completely blocked a kisspeptin-induced rise in LH (p<0.05; see Fig. 5D).
Peptide 234 inhibits LH pulses in ovariectomized ewes
Major secretory episodes of LH were clearly distinguishable in control ovariectomized ewes
and in treated ewes prior to peptide 234 administration (see Fig. 6). LH pulse amplitude was
reduced after icv administration of peptide 234 (P<0.05); this reduction in amplitude was so
marked in some ewes that it made pulse detection difficult and precluded determining if
there was an additional effect on pulse frequency. Mean LH levels were similar before and
during the infusion, but reduced following peptide 234 infusion (P<0.05; see table S2).
Peptide 234 had no effect on the concentrations of prolactin or cortisol before, during or
after infusion (See Figs. S2 and S3).
DISCUSSION
The pleiotropic effects of kisspeptin make the gpr-54 receptor an attractive therapeutic
target. Until now the emphasis has been on developing kisspeptin agonists as anti-metastatic
agents (Clements et al., 2001; Tomita et al., 2006; Orsini et al., 2007). However, the
development of kisspeptin antagonists would be of greater utility for investigating the role of
kisspeptin in the neuroendocrine regulation of gonadotropins. To realise this objective we
have systematically substituted amino acids in the minimal kisspeptin structure required for
biological activity (kisspeptin-10) and developed antagonists which have high binding
affinity, specificity and efficacy. Previous studies in pursuit of kisspeptin agonists have
established that Phe6, Arg9 and Phe10.NH2 constitute a binding pharmacophore (Orsini et
al., 2007). The evolutionary conservation of the RF.NH2 moiety amongst this large and
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ancient super-family of peptides with this motif predicts that these C-terminal residues are
essential for receptor engagement; in agreement with their identification in the
pharmacophore. Our pilot studies on kisspeptin amino acid substitutions confirmed that
changes in the RF.NH2 moiety resulted in a loss of binding. Therefore we focused on other
residues in seeking antagonist structures. First, we truncated the N-terminal five amino acids
in the rodent and human kisspeptin-10 sequences and found that this diminished agonist
activity and created incomplete antagonistic properties. Substitution of Phe6 or Leu8 in these
truncated peptides revealed that D-Trp substitution of Leu8 produced the most promising
antagonist. Incorporation of this substitution in the full decapeptide sequences produced
better antagonists especially when accompanied by the substitution of Ser5 with the achiral
amino acid, glycine, which permits greater flexibility of peptides and can obviate some of
the steric hindrances of the other amino acid substitutions that have bulky side chains (e.g.
D-Trp).
Further exploration revealed that substitution of the N-terminal Tyr1 with D-amino acids
was also tolerable for antagonistic activity but not if D-Tyr1 or D-Trp1 accompanied D-Trp8
substitution. Substitution of the pharmacophore residue Phe6 resulted in a decrease in
agonist activity and generation of some antagonist activity (e.g. 211 and 212). However,
substitution of Phe6 with D-Trp6 combined with Leu8 substitution by D-Trp8 reduced
antagonism compared with D-Trp8 alone (compare 213, 245, and 246 with 210). Certain
substitutions of Asn2 (e.g. in 232 and 236) and Trp3 (e.g. in 231 and 235) were also
acceptable for antagonism when combined with D-Trp8 substitution of Leu8. Overall a
consensus sequence for antagonism was X1-X2-X3-N-G-F-G-X8-R-F.NH where X1 2 is D-
Ala, X2 is Asn or D-Ala or D-Trp, X3 is Trp or D-Trp or D-Ala, and X8 is D-Leu, D-Phe or
D-Trp.
Our studies have also identified amino acids that appear to be involved in receptor activation
as substitution of Ser5, Leu8 and to some extent Tyr1, Asn2 and Trp3 contributed to
antagonism. This is interesting because research to date suggests that the N-terminus
contains the activation domain and the C-terminus the binding domain. Our findings
suggest, however, that the two sites overlap, as it has been shown that Phe6, Arg9 and Phe10
form a pharmacophore for binding (Orsini et al., 2007), thus placing the Leu8 activating
residue within the binding pharmacophore.
We selected peptide 234 for ex vivo and in vivo studies based on its in vitro structure-activity
profile. Since the action of kisspeptin in the HPG axis is thought to be predominantly
mediated through stimulating GnRH secretion (Irwig et al., 2004; Gottsch et al., 2006) we
first investigated the ability of peptide 234 to inhibit kisspeptin-10 stimulation of firing in
GnRH neurons recorded in acutely prepared brain slices from the mouse. Peptide 234 was
found to block kisspeptin-10 stimulation of GnRH neuron firing at 100nM, 10nM and even
at 1nM which is the same concentration as that of kisspeptin-10 used for stimulation of the
GnRH neuron.
The inhibition of kisspeptin stimulation of GnRH neuronal firing by peptide 234 suggests
that the antagonist would reduce hypothalamic GnRH secretion in vivo. Thus, we evaluated
whether peptide 234 administered directly to the stalk-median eminence region would
influence pulsatile GnRH secretion in pubertal female rhesus monkeys. The suppression of
GnRH secretion during peptide 234 infusion provides the first direct evidence that signaling
from kisspeptin neurons in the hypothalamus is a prerequisite for GnRH pulsatile secretion.
The role of kisspeptin in generating GnRH pulses was previously suggested by the
observations that kisspeptin-54 pulses coincide with GnRH pulses 75% of the time (Keen et
al., 2008). However, because clinical studies suggest that patients with gpr-54 mutations
exhibited attenuated LH pulses with an approximately normal pulse frequency (de Roux et
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al., 2003; Seminara et al., 2003), (Tenenbaum-Rakover et al., 2006), it remains equivocal
whether kisspeptin neuron input is critical for the generation of pulsatile GnRH secretion or
simply reflects modulation of GnRH pulse amplitude. The inhibition of spontaneous GnRH
pulses in the monkey model and reduction of LH pulses in the ovariectomized sheep by
peptide 234 suggests that kisspeptin is required for both frequency and amplitude of GnRH
pulsatile secretion.
Peptide 234 also blocked kisspeptin-10 stimulation of LH in adult male rats and mice
presumably by blocking kisspeptin-10 effects on GnRH secretion. In rats the inhibition was
incomplete at 1nmol 234 suggesting that the dose was insufficient. This dose completely
inhibited the kisspeptin-10 stimulation of LH in mice (possibly due to their smaller size) as
did 5nmol and 15nmol.
An unexpected finding that emerged from the studies was the absence of any inhibition of
basal LH in intact male rats and mice. This suggests that kisspeptin input is minimal under
these conditions and that other factors regulate basal GnRH and LH secretion. This
interpretation is supported by the failure of peptide 234 to affect basal firing of the GnRH
neuron (see Fig. 2), basal GnRH secretion in rhesus monkeys (see Fig. 3) and basal LH in
ovariectomized ewes (see Fig. 6). Further research and confirmation that peptide 234 does
not affect basal LH in intact females is merited as the ability to inhibit the ovulatory LH
surge but not basal LH in females might presage a long-sought contraceptive that does not
ablate endogenous estrogen yet blocks ovulation. These observations are in accordance with
the observation of variable residual gonadotropin function in KiSS-1 knock-out mice as
reflected in follicular development and sporadic ovulations (Lapatto et al., 2007).
In male mice peptide 234 blocked the increase in LH that ensues following castration and
the removal of negative feedback. A similar result was observed in castrated rats but the
inhibition was less pronounced and delayed probably due to the lower dosage employed and
the consequent requirement for a build up in peptide 234 in the brain over the 3 injections.
The findings indicate that removal of gonadal steroids leads to a rise in kisspeptin secretion
that is translated into increased GnRH and LH secretion. Previous demonstrations of
increased KiSS-1 gene expression in the arcuate nucleus in gonadectomized male and female
rats (Irwig et al., 2004; Gottsch et al., 2006) is consistent with the presumption that
kisspeptin-producing neurons are targets for the feedback actions of sex steroids (Smith et
al., 2005). Levels of mRNA may not, however, reflect the biosynthesis and secretion of
kisspeptin to engage gpr-54 expressed by GnRH neurons. Our studies with a novel
kisspeptin antagonist now provide direct evidence for kisspeptin modulation of the GnRH
neuron in negative feedback by the gonads and emphasize the value of a kisspeptin
antagonist for elucidating physiological mechanisms.
In ovariectomised sheep LH pulses (and by inference GnRH pulses) were markedly reduced
by administration of peptide 234. This is consistent with the demonstration that peptide 234
inhibited GnRH neuron firing rate in mice and reduced GnRH pulses in rhesus monkeys.
These findings imply that the endogenous secretion of kisspeptin is pulsatile in nature and
drives the ultradian secretion of GnRH. The effects of peptide 234 appear to be specific to
the regulation of gonadotropins since the antagonist had no effect on either prolactin or
cortisol secretion in ovariectomized ewes (see Figs. S2 and S3). Moreover peptide 234 did
not bind to GnRH or LH receptors (see Fig. S4).
The ability of peptide 234 to block kisspeptin-10 induced firing of GnRH neurons suggests
therapeutic potential of kisspeptin analogues in reproductive disorders associated with
abnormal LH pulse frequency characteristic of polycystic ovarian syndrome (Blank et al.,
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2006), hypothalamic amenorrhea (Armeanu et al., 1992), stress (Li et al., 2007) and in under
nutrition (e.g., anorexia nervosa) (Armeanu et al., 1992).
The inhibition of GnRH pulses in pubertal female rhesus monkeys by peptide 234 provides
support for a role for kisspeptin in the initiation of puberty. The demonstration that
kisspeptin-10 administration advanced the age of vaginal opening in female rats implicated
kisspeptin in the onset of puberty (Navarro et al., 2004). Our preliminary observation that
peptide 234 delayed vaginal opening in juvenile female rats (MS in preparation) adds further
evidence for the involvement of kisspeptin in the initiation of puberty.
A wide spectrum of pathologies is associated with dysfunction of the HPG axis and many
conditions are exacerbated by sex steroid stimulation. These include infertility, polycystic
ovarian syndrome, endometriosis, uterine fibroids, excessive menstrual bleeding, delayed
and precocious puberty, and breast, prostatic and ovarian cancers. Potent and specific
kisspeptin antagonists offer potential novel treatments for these conditions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Peptide 234 is a potent inhibitor of kisspeptin-10 stimulation of IP
Substitution of Leu8 with D-Trp in combination with Ser5 substitution with Gly created
potent antagonists (see table S1). Additional substitution of Tyr1 with D-Ala (234 shown
here) enhanced this (* p<0.05, ** p<0.01, *** p<0.001). Peptide 234 alone had no intrinsic
IP stimulation. Bars show mean ± SEM of five experiments.
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Figure 2. Peptide 234 antagonizes kisspeptin-10 excitation of GnRH neurons
Representative traces of GnRH neuronal firing rate over time. (A) Increased GnRH firing
rate after 1nM kisspeptin-10 (bar). Downward spikes are individual action currents. (B)
Inhibition of kisspeptin-10 (1nM) stimulation by peptide 234 (1 nM, bar). (C) Summary bar
graph showing mean ± SEM fold change in firing rate during baseline (white bars) and
kisspeptin-10 (black bars) kisspeptin-10 significantly increased firing activity of GnRH
neurons (n=7, * p<0.002). Response to kisspeptin-10 was significantly reduced with the
presence of 1, 10, 100 nM peptide 234 (1nM n=5, 10nM n=6, 100nM n=7, p<0.001 all
groups).
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Figure 3. Peptide 234 suppresses GnRH release in vivo
Representative cases from the effects of peptide 234 on GnRH release and group mean
(±SEM, n=6) are shown. (A) Pulsatile GnRH release in the hypothalamus was suppressed by
10 nM peptide 234 infusion to the stalk-median eminence regions (dark shaded bar). Short
arrows indicate GnRH peaks identified by PULSAR. (B) In contrast, vehicle infusion as a
control did not cause any significant changes in GnRH release (light shaded bar). (C) Data
analysis indicated that peptide 234 significantly (p<0.05) suppressed GnRH release as
compare to levels prior to peptide 234 as well as to the vehicle control. (D) Vehicle infusion
did not cause any significant changes. The estimated concentration of peptide 234 in the
stalk-median eminence region was 1 nM, based on our previous assessment that the dialysis
membrane passes ∼10% of peptides with a similar size. * p<0.05 vs. before peptide 234; a
p<0.05 vs. control at corresponding time period.
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Figure 4. Peptide 234 effects on basal and kisspeptin-10-stimulated plasma LH in intact and
castrated male rats
Peptide 234 (A) inhibits kisspeptin-10 induced LH secretion in intact male rats. The animals
were infused with 1nmol peptide 234 at 0 and 60 min, followed by infusion of 100pmol
kisspeptin-10 with 1nmol peptide 234 at 120mins. The peptide significantly inhibited LH
production over the following 2 hours (n=10; * = p<0.05). (B) Castrated male rats were
given three infusions of 1nmol peptide 234 at 0, 60 and 120 min, which significantly
inhibited LH secretion after 240 min with 1nmol peptide 234 (n=10; p<0.05). Bars show
mean ± SEM.
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Figure 5. Peptide 234 inhibition of plasma LH in male mice
(A) Two infusions of 15 nmol of peptide 234 inhibit the elevated LH levels of castrated
male mice. (B) Dose response graph for castrated male mice given two infusions of peptide
234 indicates that all 3 doses tested are able to inhibit the post-castration rise in LH. (C)
Likewise, a single infusion of 5 nmol or 15 nmol of peptide 234 potently inhibits LH levels
of castrated mice. (D) Exogenously administered kisspeptin (100fmol) is unable to stimulate
LH levels in intact male mice when 100pmol peptide 234 is infused 5 min beforehand
(n=6-8). Bars show mean ± SEM.
Roseweir et al. Page 22













Figure 6. Central infusion of peptide 234 inhibits the secretory pulses of LH in OVX ewes
Concentrations of LH are shown in ewes treated with peptide 234 (closed bars) or control
(opened bars). Arrows indicate LH pulses as defined in the supporting materials and
methods. Analysis revealed a significant reduction in the mean LH concentration and pulse
amplitude after peptide 234 infusion (see table S2).
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